CompletedPhase IInterventional

Phase I Trial: Quotient Code QSC303217

This is an early-stage medical study known as Quotient Code QSC303217. It's the very first step in testing a new treatment. At this stage, researchers are mainly checking to see if a new treatment is safe and what the right dose might be. The full details about what this study is investigating and how it works are not yet available to the public. This is a common practice, and all the information will be published within 30 months after the study has officially ended. The study is open to adults between 18 and 65 years old, and both men and women can take part. More specific details about who can and cannot join will be shared when the full study information is released.

At a glance

Status

Completed

Phase

Phase I

Sponsor

Aardvark Therapeutics, Inc.

Enrolment target

Start

01 Jul 2025

Estimated completion

22 Aug 2025

The sponsor has confirmed that the trial meets the criteria for deferral of publication of the full details of the trial. Full details will be added to the study record within 30 months after the trial has ended.

What is this study about?

This study, called Quotient Code QSC303217, is an early phase clinical trial. This means it's one of the very first times a new potential treatment is being tested in people. The main goal of these early studies is to check for safety, understand how the body handles the new treatment, and find the right dose that might work. It's an important step before larger studies can investigate how well a treatment works.

At this moment, the full details about this particular study, including what specific condition it aims to help with or what exactly the new treatment is, haven't been shared publicly. This is sometimes agreed upon to protect sensitive information while the research is ongoing. However, all this information will be made available and published within 30 months after the study reaches its end.

This early stage research is vital for developing new medicines. By taking part, volunteers help scientists learn more about potential new treatments, which could eventually benefit many people. It's about gathering initial information carefully and responsibly.

Key takeaways

This is an early (Phase I) study, checking safety of a new treatment.
Full study details will be released within 30 months after completion.
Open to adults aged 18-65, men and women.
Participation involves regular check-ups and close monitoring.
You can stop participating at any time.
Helps advance medical knowledge for future treatments.

Who may be eligible?

Currently, we know the study is open to adults who are between 18 and 65 years old. Both men and women can take part in this research.

As this is an early-stage study, there will be very careful rules about who can join to make sure it's as safe as possible for participants. These rules might include specific health conditions you have, medicines you take, or other details about your medical history.

Because the full information about this study is not yet public, we don't have all the specific details about who definitely can or cannot join. These important details, including any health conditions that might prevent you from taking part, will be released and made clear within 30 months after the study finishes.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you between 18 and 65 years old?
Are you able to commit to regular visits for medical checks?
Are you comfortable with receiving an investigational treatment?
Are you willing to have your health closely monitored?

Answer every question to see your result.

What does participation involve?

Because the full study details are not yet public, we don't have specific information about what taking part in this study would involve. However, in an early-stage study like this, you would typically expect:

* **Screening visits:** Before joining, you would have medical checks, tests, and discussions with the study team to ensure you meet the strict entry rules. * **Regular visits:** If you join, you'd likely attend a research clinic or hospital often for follow-up appointments, medical examinations, blood tests, and to receive the study treatment. * **Receiving medication:** You would receive the new treatment being tested, likely in a controlled environment, and the research team would closely monitor how your body reacts. * **Close monitoring:** Researchers would keep a very close eye on your health and any side effects. This might include diaries to record symptoms. * **Follow-up:** Even after you stop receiving the treatment, there might be follow-up appointments to ensure your health is stable. * **Duration:** The total length of your involvement could range from a few weeks to several months, depending on the study design.

Potential risks and benefits

Participating in any clinical trial involves both potential benefits and potential risks. A potential benefit could be contributing to medical science and helping to develop new treatments that might help others in the future. In early-stage studies, there's less chance of personal health benefits from the experimental treatment itself, as the main goal is safety. Potential risks include experiencing side effects from the new treatment, which may not yet be fully known, or discomfort from medical procedures like blood tests. It's very important to remember that joining a study is always voluntary, and you have the right to withdraw at any time without giving a reason, and without affecting your usual medical care.

Locations (1)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Quotient Sciences Limited
City only
Nottingham, United Kingdom

Common questions

What is an early-stage (Phase I) study?

It's the first time a new treatment is tested in people. Researchers check if it's safe and try to find the right dosage.

When will I know more about this specific study?

The full details will be made public within 30 months after the study has officially ended.

Who can take part in this study?

Currently, we know it's for adults aged 18 to 65, both men and women. More specific health requirements will be shared later.

Will I get the new treatment if I join?

Yes, if you meet all the criteria and are enrolled, you would receive the investigational treatment being tested.

Can I leave the study at any time?

Yes, your participation is voluntary, and you can withdraw from the study at any point without any consequences to your healthcare.

How to find out more

Terrie Kellmeyer

Info@AardvarkTherapeutics.com +1 (858) 225-7696 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.